drugset / Trial / NCT01441414

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

NCT01441414

Phase 2 Terminated 18 enrolled Pfizer
RandomizedOpen-labelTreatment

Summary

To evaluate the combination of PF-04856884 (CVX-060) in combination with Axitinib (AG-013736) in patients that have received one prior systemic regimen for metastatic renal cell carcinoma (mRCC) vs. axitinib alone.

Timeline

Start
2011-11-21
Primary completion
2014-03-27
Completion
2014-03-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Axitinib Small molecule 5 mg Oral
Subject CVX-060 Protein / enzyme biologic 15 mg/kg Intravenous

Indications